Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM Journal of Clinical and Translational Endocrinology Pub Date : 2022-06-01 DOI:10.1016/j.jcte.2022.100298

Laurence Weiss , Olivia Ronsin , Quitterie Reynaud , Michel Abely , Laurent Mely , Pierre-Régis Burgel , Jacques Beltrand , Laurence Kessler

{"title":"Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers","authors":"Laurence Weiss , Olivia Ronsin , Quitterie Reynaud , Michel Abely , Laurent Mely , Pierre-Régis Burgel , Jacques Beltrand , Laurence Kessler","doi":"10.1016/j.jcte.2022.100298","DOIUrl":null,"url":null,"abstract":"<div><p>This study aimed to analyze clinical practices concerning cystic fibrosis-related diabetes (CFRD) screening in France. A web-based questionnaire was distributed between December 1, 2020 and January 31, 2021 among 47 cystic fibrosis centers including pediatric, adult, and mixed units. In accordance with guidelines, 92.8% of CF centers performed annual oral glucose tolerance tests (OGTT). Overall, 86.3% of CF centers performed 1- and 2-hour blood glucose determinations following OGTT. The OGTT was conducted before 10 years of age in 73% of pediatric centers. Continuous glucose monitoring (CGM) and laboratory glycated hemoglobin were employed for CFRD screening in 86.5% and 50% of centers, respectively. CGM was carried out in 69% of centers after glucose tolerance abnormalities had been detected in OGTT. Most CF centers used OGTT and CGM for CFRD screening. Studies are required to assess CGM usefulness as a validated tool in CFRD screening.</p></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":null,"pages":null},"PeriodicalIF":4.2000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2214623722000060/pdfft?md5=c6ae918f7c8c6247a678efb230158d51&pid=1-s2.0-S2214623722000060-main.pdf","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Translational Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214623722000060","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 4

Abstract

This study aimed to analyze clinical practices concerning cystic fibrosis-related diabetes (CFRD) screening in France. A web-based questionnaire was distributed between December 1, 2020 and January 31, 2021 among 47 cystic fibrosis centers including pediatric, adult, and mixed units. In accordance with guidelines, 92.8% of CF centers performed annual oral glucose tolerance tests (OGTT). Overall, 86.3% of CF centers performed 1- and 2-hour blood glucose determinations following OGTT. The OGTT was conducted before 10 years of age in 73% of pediatric centers. Continuous glucose monitoring (CGM) and laboratory glycated hemoglobin were employed for CFRD screening in 86.5% and 50% of centers, respectively. CGM was carried out in 69% of centers after glucose tolerance abnormalities had been detected in OGTT. Most CF centers used OGTT and CGM for CFRD screening. Studies are required to assess CGM usefulness as a validated tool in CFRD screening.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

囊性纤维化相关糖尿病筛查的临床实践与指南:一项来自法国47个中心的调查

本研究旨在分析法国囊性纤维化相关性糖尿病(CFRD)筛查的临床实践。在2020年12月1日至2021年1月31日期间，在47个囊性纤维化中心(包括儿科、成人和混合单位)分发了一份基于网络的问卷。根据指南，92.8%的CF中心每年进行口服葡萄糖耐量试验(OGTT)。总体而言，86.3%的CF中心在OGTT后进行了1小时和2小时血糖测定。在73%的儿科中心，OGTT是在10岁前进行的。分别有86.5%和50%的中心采用连续血糖监测(CGM)和实验室糖化血红蛋白筛查CFRD。在OGTT中检测到糖耐量异常后，69%的中心进行了CGM。大多数CF中心使用OGTT和CGM筛查CFRD。需要研究来评估CGM作为CFRD筛查的有效工具的有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊